Complete the Phase 2a NASH clinical trial
Delivered after the deadline (13 days after the deadline)
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 28 Jan 2021
- Due
- 30 Jun 2021
- Delivered
- 13 Jul 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Phase 2a ongoing – completion Q2 2021”
What we found
Evidence strength A What the grades mean
The company announced topline results for the Phase 2a NASH clinical trial on July 13, 2021, which occurred shortly after the Q2 2021 deadline.
-
A Hepion Pharmaceuticals, Inc. 10-Q filed 2021-08-16
“On July 13, 2021, we announced positive topline results from our Phase 2a "Ambition" NASH clinical trial.” ✓ confirmed on the page
Market reaction: the shares moved +1.5% against the S&P 500 over the three sessions around the disclosure (13 Aug 2021 to 18 Aug 2021). What this measures
Checked 25 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Complete
- Deliverable
- Phase 2a NASH clinical trial
- In the company’s control
- Medium
- Specificity
- High
- Depends on
- Customer
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Hepion Pharmaceuticals, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-HEPA-022559 · Corrections policy